Search

Filter:

Search Results

Profectus begins PhI HIV vax trial with 'prime-boost' delivery

Profectus BioSciences, a vaccine developer with a focus on DNA-based applications, began a Phase I clinical trial of its HIV vaccine, which makes use of the TriGrid electroporation delivery system the company licensed from Ichor Medical Systems. Using a "prime-boost" vaccination regimen, ...

Veritas wins European patent for RNA delivery method

allowed in the U.S. already, and is in the process of filing other applications to expand its RNA-drug ...

Actavis rolls out generic Lidoderm patch; Daiichi shares plunge on new FDA import restrictions;

Visterra antibody shows promise in preclinical study as universal flu vaccine. Item > NIH partners with Eli Lilly, others on rare diseases. Article > Experimental vaccine clears monkeys of HIV-like ...

Troubled Dendreon gets EC OK for Provenge; Acacia launches pivotal studies;

> Visterra antibody shows promise in preclinical study as universal flu vaccine.  Item > NIH partners with Eli Lilly, others on rare diseases.  Article > Experimental vaccine clears monkeys ...

Biotechs keep the cash pumping (for now) with more IPOs and ATMs

PhII Langer's Bind files $80M IPO as new biotech offerings go gangbusters Five Prime Therapeutics ...

Boston Scientific scores solid results for TAVR device; JenaValve nails down expanded CE mark;

promise in preclinical study as universal flu vaccine.  Item > NIH partners with Eli Lilly, others on rare diseases.  Article > Experimental vaccine clears monkeys of HIV-like virus.  More > Genia ...

Boston Scientific, OrbusNeich call cease-fire in stent fight

including the top-selling Promus Element and newly released Promus Premier. OrbusNeich first filed suit ...

UPDATED: Strides gets FDA warning for plant Mylan is buying

drug unit it is selling to Mylan ($MYL) for $1.6 billion. In a filing with the Indian stock exchange, ...

Veeva, provider of sales software to Merck, seeks up to $150M in IPO

in April that Veeva was likely to attempt an IPO this year.- here's the S-1 filing- and an article ...

Unvaccinated clusters bear brunt of bad year for measles in U.S.

the 10% of people who decline the measles vaccine are distributed. Most of the country is above the 90% immunization target, but in certain communities the vaccination rate is much lower. When a virus is introduced ...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • next ›
  • last »